Brokerages predict that Integra Lifesciences Holdings Corp (NASDAQ:IART) will announce earnings per share (EPS) of $0.61 for the current fiscal quarter, according to Zacks Investment Research. Six analysts have issued estimates for Integra Lifesciences’ earnings. The lowest EPS estimate is $0.59 and the highest is $0.63. Integra Lifesciences posted earnings of $0.58 per share in the same quarter last year, which would indicate a positive year over year growth rate of 5.2%. The business is scheduled to report its next earnings report on Wednesday, April 24th.
On average, analysts expect that Integra Lifesciences will report full-year earnings of $2.68 per share for the current financial year, with EPS estimates ranging from $2.63 to $2.70. For the next year, analysts expect that the firm will report earnings of $2.99 per share, with EPS estimates ranging from $2.96 to $3.02. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that that provide coverage for Integra Lifesciences.
Integra Lifesciences (NASDAQ:IART) last released its quarterly earnings data on Thursday, February 21st. The life sciences company reported $0.65 earnings per share for the quarter, topping the consensus estimate of $0.62 by $0.03. Integra Lifesciences had a return on equity of 16.02% and a net margin of 4.13%. The business had revenue of $383.30 million during the quarter, compared to analysts’ expectations of $382.33 million. During the same quarter last year, the business posted $0.64 EPS. The business’s revenue was up 4.0% on a year-over-year basis.
Large investors have recently made changes to their positions in the company. Oregon Public Employees Retirement Fund increased its position in Integra Lifesciences by 4,410.0% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 1,254,051 shares of the life sciences company’s stock valued at $28,000 after buying an additional 1,226,245 shares in the last quarter. Enlightenment Research LLC bought a new position in Integra Lifesciences during the 4th quarter valued at approximately $32,000. Legacy Financial Advisors Inc. bought a new position in Integra Lifesciences during the 4th quarter valued at approximately $33,000. Fort L.P. bought a new position in Integra Lifesciences during the 4th quarter valued at approximately $34,000. Finally, Executive Wealth Management LLC bought a new position in Integra Lifesciences during the 4th quarter valued at approximately $38,000. 83.11% of the stock is owned by hedge funds and other institutional investors.
NASDAQ IART opened at $56.14 on Friday. Integra Lifesciences has a fifty-two week low of $42.14 and a fifty-two week high of $67.50. The company has a debt-to-equity ratio of 0.97, a current ratio of 2.95 and a quick ratio of 1.88. The company has a market capitalization of $4.72 billion, a price-to-earnings ratio of 23.20, a price-to-earnings-growth ratio of 1.63 and a beta of 0.96.
Integra Lifesciences Company Profile
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.
Recommended Story: Derivative
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.